Pooled analyses show NILEMDO ® ▼ significantly lowers cholesterol in different subgroups in Phase 3 data presented at AHA 2020
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced results from two pooled analyses from four Phase 3 clinical trials for bempedoic acid. The data were presented at the virtual American Heart Association (AHA) Scientific Sessions 2020.
One pooled analysis including 3,621 patients explored low-density lipoprotein cholesterol (LDL-C) reduction in male participants compared to female participants across two pools of patients; an on-statins pool and a statin-intolerant pool.**3 Results showed that bempedoic acid significantly lowered LDL-C at Week 12 in both sexes compared with placebo.3 In the on-statins pool bempedoic acid significantly reduced LDL-C by 21.2% in female participants vs. 17.4% in male participants (placebo-corrected; interaction p value = 0.044). In the statin-intolerant pool LDL-C was reduced by 27.7% in female participants vs. 22.1% in male participants (placebo-corrected; interaction p value = 0.079), which was not statistically significant.3 Baseline levels of LDL-C were slightly higher in female participants.3 Bempedoic acid was generally well tolerated by both sexes in both pools.3
In Europe, cardiovascular disease causes a greater proportion of deaths among women (51%) than men (42%) overall, killing twice as many women as all forms of cancer combined.4 Evidence shows that women have often been underrepresented in clinical trials of lipid-lowering therapies and cardiovascular outcomes, and analyses of trial data by sex are deficient in cardiovascular research.4,5
“These data demonstrate the benefits of bempedoic acid in both women and men who struggle to keep their LDL-C levels low, many of whom are already taking other lipid-lowering therapies to try and reach their recommended LDL-C levels,” said Anne C Goldberg, Professor of Medicine, Washington University School of Medicine, USA. “As women have been historically underrepresented in clinical trials, and we know that both sexes are affected differently by disease, these results presented today are important in analysing the sexes separately and understanding the impact of treatment on both groups.”
“It is important for the future of patient care that we examine bempedoic acid data across multiple subgroups to help identify different patients that may benefit from this treatment. These data further add to the robust evidence behind bempedoic acid as an option that can be added on to existing lipid-lowering therapies to further reduce LDL-C levels, helping patients take back control of their cholesterol,” said Wolfgang Zierhut MD, Head Antithrombotic and Cardiovascular Therapeutic Area at Daiichi Sankyo Europe. “With up to 80% of patients not reaching guideline-recommended LDL-C goals despite receiving treatments such as statins and other lipid-lowering therapies, we are committed to continuing to help provide solutions to support these patients.”
The second pooled analysis presented at AHA 2020 assessed the efficacy and safety of bempedoic acid in patients from four Phase 3 clinical trials who were unable to tolerate statins.6 Results showed that bempedoic acid significantly reduced LDL-C by an average of –26.5% (95% CI: –29.7, –23.2) vs. placebo in patients unable to use statins. Bempedoic acid was shown to be generally well-tolerated in patients with hypercholesterolaemia unable to tolerate a statin.6
*Note: Daiichi Sankyo Europe strives to be inclusive in our language. In this press release, we follow the recommendation for reporting of demographic data in research articles of the language guidance outlined in “Reporting Sex, Gender, or Both in Clinical Research?” from The Journal of the American Medicine Association (JAMA). November 8, 2016 Volume 316, Number 18
**Note: the on-statins pool were patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) who were receiving background lipid-lowering therapy, including maximally tolerated statins. The statin-intolerant pool were patients with a history of problems taking statins and included patients who were taking no statins or no more than the lowest approved starting dose of a statin.
– ENDS –
NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.1 NILEMDO® inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.1
NILEMDO® has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet1
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
NILEMDO® acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other lipid-lowering therapies.1 Due to its unique mechanism of action, NILEMDO® is not activated in skeletal muscle which decreases the potential for muscle-related side effects.1,2
NUSTENDI® is a new oral treatment which combines two complementary ways of reducing cholesterol in a convenient once-daily tablet. NUSTENDI® is a fixed dose combination tablet containing bempedoic acid (the active pharmaceutical ingredient in NILEMDO®) and ezetimibe.7
NUSTENDI® has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:7
- in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,
- alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,
- in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without a statin.
Daiichi Sankyo Europe has licensed exclusive commercialisation rights to NILEMDO® and NUSTENDI® in the European Economic Area, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centred around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
1 European Medicines Agency. NILEMDO® Summary of Product Characteristics. March 2020.
2 Pinkosky SL, et al. Liver- specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Communications. 2016; 7:13457. DOI:10.1038/ncomms13457.
3 Goldberg AC, et al. Efficacy and safety of bempedoic acid by sex: pooled analyses from phase 3 trials. Poster presentation at American Heart Association Scientific Sessions. November 2020, Abstract P742.
4 Tamargo J, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J CardiovascPharmacother. 2017; 3:163-182.
5 Cholesterol Treatment Trialists' (CTT) Collaboration, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385:1397-1405.
6 Laufs U, et al. Efficacy and safety of bempedoic acid in patients who cannot tolerate any dose of a statin: pooled analyses from phase 3 clinical trials. Poster presentation at American Heart Association Scientific Sessions. November 2020, Abstract P2139.
7 European Medicines Agency. NUSTENDI® Summary of Product Characteristics. March 2020.
Dr. Wolfgang Schiessl (Europe)
Daiichi Sankyo Europe GmbH
Director Product PR and Communications, Cardiovascular Europe
+49 151 1714 7317
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales NS50 Radar to Equip the Belgium Navy and the Royal Netherlands Navy Next Generation Mine Counter Measures Vessels (MCMV)20.1.2021 10:00:00 CET | Press release
The navies of Belgium and the Netherlands rely on Thales, Naval Group and KERSHIP shipyard to equip the 12 next generation Mine Counter Measures Vessels with NS50 radars for Air & Surface Surveillance with Fire Control capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210120005024/en/ NS50 radar © Thales The NS50 provides for the first time a complete and superior level of self-protection capability against air and surface threats for this category of high value MCM vessels. A strategic choice for small to medium vessels, the NS50 offers dual functions between air and surface surveillance and fire control. The nature of threats faced by Navies has never been more varied nor more challenging, ranging from next generation anti-ship missiles, robotic warfare and swarm attacks, to electronic warfare (jamming) as well as, overall, having to operate in a simultaneously conventional, asymmetric and hybrid threat environm
SmartStream Reveal Their Latest API Suite With a Complete Range of Reference Data Services20.1.2021 10:00:00 CET | Press release
SmartStream Technologies, the financial Reference Data Utility (RDU) solutions provider, today announces the launch of its Application Programming Interface (API) suite – for quicker access to services providing accurate data, with improved customer service, operational efficiency, greater agility and competitiveness. The new fully comprehensive API service will benefit financial institutions by saving huge amounts on infrastructure costs, as well as an affordable service which is straightforward to deploy. Financial institutions are now realising the need for change, with many currently engaging in digital transformation projects including the implementation of APIs. RDU services currently fall into two categories: security reference data and regulatory reference data. Security reference data solutions available on an API basis will include a listed derivatives service, with data sourced from over 100 exchanges and comprehensive coverage for options, futures, options on futures and ca
Wiztopic and Euronext Corporate Services Sign a Commercial Partnership20.1.2021 08:00:00 CET | Press release
Wiztopic, the cloud-based provider of software solutions for corporate communications, public relations and investor relations professionals, today announced a commercial partnership with Euronext Corporate Services, a subsidiary of Euronext, providing companies with innovative solutions and tailor-made advisory services in the areas of governance, compliance, communication, and investor relations. This strategic alliance will simplify the access to highly complementary solutions for their respective customers. The combination of Euronext Corporate Services and Wiztopic’s solutions constitutes a suite of best-in-class digital communication solutions to satisfy the increasingly sophisticated needs of time-poor corporate communication, PR and IR professionals. Euronext Corporate Services’ clients will benefit from Wiztrust’s blockchain certification platform to secure their financial communications and avoid fake news. "This partnership solidifies Wiztrust as the European platform for ce
ENHERTU ® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer20.1.2021 08:00:00 CET | Press release
Daiichi Sankyo Company, Limited(hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (trastuzumab deruxtecan) has been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens. In Europe, approximately 531,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive.1,2,3 The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths per year in Europe.1 “One in five women with breast cancer have HER2 positive disease and those with previously-treated metastatic disease often progress quickly,” said Professor Fabrice André, Head of Research, Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. “One of the biggest challenges in this setting has been identifying treatment strategies that produce a
Bureau Veritas Further Expands Cybersecurity Offer by Joining Forces With Secura20.1.2021 08:00:00 CET | Press release
Bureau Veritas, a world leader in testing, inspection and certification,announced today that it has completed the acquisition of Secura B.V. (starting with a majority stake), an independent service company specializing in cybersecurity services.Secura will be a cornerstone in the cybersecurity strategy of Bureau Veritas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119006117/en/ Rising demand in digital security and new regulations drive a growing need for conformity assessments. As a result, Testing, Inspection and Certification (TIC) services for cybersecurity are an emerging market with substantial expected growth and significant momentum. In this promising new conformity market, Secura is a recognized cybersecurity player with a strong orientation toward TIC activities. Established in 2000 in the Netherlands, Secura has 100 employees located in two technological centers in Eindhoven and Amsterdam. The company posted
CYNORA Announces Availability of Industry’s First Device Test Kits for TADF Deep Green Emitters for Next-Generation OLED Displays20.1.2021 07:00:00 CET | Press release
Marking a new innovation trajectory for the OLED industry, CYNORA today announced that device test kits for its Thermally Activated Delayed Fluorescence (TADF)-based Deep Green emitter for next-generation OLED displays are now available to customers. The development is an industry-first milestone for TADF technology, and validates CYNORA’s roadmap commitment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119006159/en/ cyUltimateGreen™ - CYNORA's TADF Deep Green Emitter Device Test Kit (Photo: Dr. Harald Flügge, CYNORA) Known as the cyUltimateGreen™, the product delivers efficiency of more than 20 percent, which meets current industry specifications of 150cd/A in top emission devices. It demonstrates lifetime of 400h LT95@15mA, and color point and spectra that match today’s DCI-P3 standard. In addition, the product shows compatibility with BT2020, a color standard that requires greater color purity than DCI-P3, and one th
Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs20.1.2021 07:00:00 CET | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005966/en/ Gwenan White, Executive Vice President, Communications and Public Affairs, Ipsen (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Gwenan White as Executive Vice President, Communications and Public Affairs, effective March 2021. Based in Boulogne, France, she will be responsible for designing, implementing and managing the communications and public affairs strategy for Ipsen at global level, reporting directly to David Loew, CEO, Ipsen. Gwenan will serve on the Executive Leadership Team. “Along with the ELT, we are very pleased to welcome Gwenan to Ipsen. She will be critical to the implementation of our new strategy, Focus. Together. For patients & society. Her background in communications and public affairs will help reinforce Ipsen’s position as partner and employer of choice and will contribute to d